Absolutely. Right now sp is completely supported by optune. Once DCVax-L has approval, NVCR will be in tail-spin mode. This pattern of CEO selling his shares since the publication of the first paper on the p3 trial of DCVax-L in May 2018 happens to every member of the C-suite of NVCR. It couldn't be more obvious.